BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33683866)

  • 1. Recapitulating the Binding Affinity of Nrf2 for KEAP1 in a Cyclic Heptapeptide, Guided by NMR, X-ray Crystallography, and Machine Learning.
    Ortet PC; Muellers SN; Viarengo-Baker LA; Streu K; Szymczyna BR; Beeler AB; Allen KN; Whitty A
    J Am Chem Soc; 2021 Mar; 143(10):3779-3793. PubMed ID: 33683866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic molecular dynamics approach to the study of peptide Keap1-Nrf2 protein-protein interaction inhibitors and its application to p62 peptides.
    Lu MC; Yuan ZW; Jiang YL; Chen ZY; You QD; Jiang ZY
    Mol Biosyst; 2016 Apr; 12(4):1378-87. PubMed ID: 26935067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1.
    Unni S; Deshmukh P; Krishnappa G; Kommu P; Padmanabhan B
    FEBS J; 2021 Mar; 288(5):1599-1613. PubMed ID: 32672401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kelch-like ECH-associated protein 1 (KEAP1) differentially regulates nuclear factor erythroid-2-related factors 1 and 2 (NRF1 and NRF2).
    Tian W; Rojo de la Vega M; Schmidlin CJ; Ooi A; Zhang DD
    J Biol Chem; 2018 Feb; 293(6):2029-2040. PubMed ID: 29255090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational cyclization-based minimization of entropy penalty upon the binding of Nrf2-derived linear peptides to Keap1: A new strategy to improve therapeutic peptide activity against sepsis.
    Chen K; Huang L; Shen B
    Biophys Chem; 2019 Jan; 244():22-28. PubMed ID: 30465941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Binding Energy of Keap1 Interaction Motifs in the Nrf2 Antioxidant Pathway and Design of Potential High-Affinity Peptides.
    Karttunen M; Choy WY; Cino EA
    J Phys Chem B; 2018 Jun; 122(22):5851-5859. PubMed ID: 29745220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.
    Davies TG; Wixted WE; Coyle JE; Griffiths-Jones C; Hearn K; McMenamin R; Norton D; Rich SJ; Richardson C; Saxty G; Willems HM; Woolford AJ; Cottom JE; Kou JP; Yonchuk JG; Feldser HG; Sanchez Y; Foley JP; Bolognese BJ; Logan G; Podolin PL; Yan H; Callahan JF; Heightman TD; Kerns JK
    J Med Chem; 2016 Apr; 59(8):3991-4006. PubMed ID: 27031670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a steady-state FRET-based assay to identify inhibitors of the Keap1-Nrf2 protein-protein interaction.
    Schaap M; Hancock R; Wilderspin A; Wells G
    Protein Sci; 2013 Dec; 22(12):1812-9. PubMed ID: 24130096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Activity and Structure-Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1/NRF2) Protein-Protein Interaction.
    Heightman TD; Callahan JF; Chiarparin E; Coyle JE; Griffiths-Jones C; Lakdawala AS; McMenamin R; Mortenson PN; Norton D; Peakman TM; Rich SJ; Richardson C; Rumsey WL; Sanchez Y; Saxty G; Willems HMG; Wolfe L; Woolford AJ; Wu Z; Yan H; Kerns JK; Davies TG
    J Med Chem; 2019 May; 62(9):4683-4702. PubMed ID: 30973731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction Energetics and Druggability of the Protein-Protein Interaction between Kelch-like ECH-Associated Protein 1 (KEAP1) and Nuclear Factor Erythroid 2 Like 2 (Nrf2).
    Zhong M; Lynch A; Muellers SN; Jehle S; Luo L; Hall DR; Iwase R; Carolan JP; Egbert M; Wakefield A; Streu K; Harvey CM; Ortet PC; Kozakov D; Vajda S; Allen KN; Whitty A
    Biochemistry; 2020 Feb; 59(4):563-581. PubMed ID: 31851823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
    Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
    J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors.
    Mou Y; Wen S; Li YX; Gao XX; Zhang X; Jiang ZY
    Eur J Med Chem; 2020 Sep; 202():112532. PubMed ID: 32668381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a Kelch-like ECH-associated protein 1-inhibitory tetrapeptide and its structural characterization.
    Sogabe S; Sakamoto K; Kamada Y; Kadotani A; Fukuda Y; Sakamoto JI
    Biochem Biophys Res Commun; 2017 May; 486(3):620-625. PubMed ID: 28315327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into the mechanism of Keap1-Nrf2 interaction based on cancer-associated mutations.
    Cheng L; Wang H; Li S; Liu Z; Wang C
    Life Sci; 2021 Oct; 282():119791. PubMed ID: 34229009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency.
    Lu MC; Jiao Q; Liu T; Tan SJ; Zhou HS; You QD; Jiang ZY
    Eur J Med Chem; 2018 Jan; 143():1578-1589. PubMed ID: 29117896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of novel small-molecule NRF2 activators: Structural and biochemical validation of stereospecific KEAP1 binding.
    Huerta C; Jiang X; Trevino I; Bender CF; Ferguson DA; Probst B; Swinger KK; Stoll VS; Thomas PJ; Dulubova I; Visnick M; Wigley WC
    Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2537-2552. PubMed ID: 27474998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds.
    Pallesen JS; Narayanan D; Tran KT; Solbak SMØ; Marseglia G; Sørensen LME; Høj LJ; Munafò F; Carmona RMC; Garcia AD; Desu HL; Brambilla R; Johansen TN; Popowicz GM; Sattler M; Gajhede M; Bach A
    J Med Chem; 2021 Apr; 64(8):4623-4661. PubMed ID: 33818106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling.
    Lo SC; Li X; Henzl MT; Beamer LJ; Hannink M
    EMBO J; 2006 Aug; 25(15):3605-17. PubMed ID: 16888629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel inhibitors of Keap1/Nrf2 by a promising method combining protein-protein interaction-oriented library and machine learning.
    Shimizu Y; Yonezawa T; Sakamoto J; Furuya T; Osawa M; Ikeda K
    Sci Rep; 2021 Apr; 11(1):7420. PubMed ID: 33795749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of linear and cyclic peptide inhibitors of KEAP1-NRF2 protein-protein interaction.
    Colarusso S; De Simone D; Frattarelli T; Andreini M; Cerretani M; Missineo A; Moretti D; Tambone S; Kempf G; Augustin M; Steinbacher S; Munoz-Sanjuan I; Park L; Summa V; Tomei L; Bresciani A; Dominguez C; Toledo-Sherman L; Bianchi E
    Bioorg Med Chem; 2020 Nov; 28(21):115738. PubMed ID: 33065433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.